Overview

Study Comparing Ranibizumab Monotherapy With Combined Verteporfin Therapy in Subfoveal CNV

Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
This pilot study is designed to evaluate the safety and efficacy of intravitreal ranibizumab used in combination with verteporfin photodynamic therapy (Visudyne®) compared to ranibizumab monotherapy for the treatment of subfoveal CNV secondary to AMD
Phase:
Phase 3
Details
Lead Sponsor:
University Hospital, Basel, Switzerland
Treatments:
Ranibizumab
Verteporfin